Please wait while the formulary information is being retrieved.
Drug overview for NOVOLOG MIX 70-30 FLEXPEN (insulin aspart protamine human/insulin aspart):
Generic name: INSULIN ASPART PROTAMINE HUMAN/INSULIN ASPART (IN-sue-lin AS-part PRO-tah-meen/ IN-sue-lin AS-part)
Drug class: Intermediate-, Long-acting, and Combination Insulins
Therapeutic class: Endocrine
Insulin aspart (rDNA origin) is a biosynthetic, rapid-acting human insulin analog that is prepared using recombinant DNA technology and genetically modified Saccharomyces cerevisiae.
No enhanced Uses information available for this drug.
Generic name: INSULIN ASPART PROTAMINE HUMAN/INSULIN ASPART (IN-sue-lin AS-part PRO-tah-meen/ IN-sue-lin AS-part)
Drug class: Intermediate-, Long-acting, and Combination Insulins
Therapeutic class: Endocrine
Insulin aspart (rDNA origin) is a biosynthetic, rapid-acting human insulin analog that is prepared using recombinant DNA technology and genetically modified Saccharomyces cerevisiae.
No enhanced Uses information available for this drug.
DRUG IMAGES
- No Image Available
The following indications for NOVOLOG MIX 70-30 FLEXPEN (insulin aspart protamine human/insulin aspart) have been approved by the FDA:
Indications:
Diabetes mellitus
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Professional Synonyms:
Adult onset diabetes mellitus
Adult onset diabetes
Adult onset DM
Diabetes mellitus type 1
Diabetes mellitus type 2
Diabetes mellitus type II
Immune mediated diabetes mellitus
Insulin dependent diabetes mellitus
Insulin-dependent diabetes mellitus
Insulin-dependent DM
Juvenile diabetes
Juvenile onset DM
Juvenile-onset diabetes mellitus
Juvenile-onset diabetes
Ketosis-prone diabetes mellitus
Ketosis-prone diabetes
Ketosis-prone DM
Ketosis-resistant diabetes mellitus
Ketosis-resistant DM
Maturity onset diabetes mellitus
Maturity onset diabetes
Non-insulin dependent diabetes mellitus
Non-insulin-dependent diabetes mellitus
Type I diabetes mellitus
Type II diabetes mellitus
Indications:
Diabetes mellitus
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Professional Synonyms:
Adult onset diabetes mellitus
Adult onset diabetes
Adult onset DM
Diabetes mellitus type 1
Diabetes mellitus type 2
Diabetes mellitus type II
Immune mediated diabetes mellitus
Insulin dependent diabetes mellitus
Insulin-dependent diabetes mellitus
Insulin-dependent DM
Juvenile diabetes
Juvenile onset DM
Juvenile-onset diabetes mellitus
Juvenile-onset diabetes
Ketosis-prone diabetes mellitus
Ketosis-prone diabetes
Ketosis-prone DM
Ketosis-resistant diabetes mellitus
Ketosis-resistant DM
Maturity onset diabetes mellitus
Maturity onset diabetes
Non-insulin dependent diabetes mellitus
Non-insulin-dependent diabetes mellitus
Type I diabetes mellitus
Type II diabetes mellitus
The following dosing information is available for NOVOLOG MIX 70-30 FLEXPEN (insulin aspart protamine human/insulin aspart):
Because of its short duration of action, insulin aspart is used concomitantly with a longer-acting insulin (e.g., isophane (NPH) insulin human, insulin aspart protamine) to meet basal insulin needs in patients with diabetes mellitus and to provide more optimal glycemic control. Initial total daily insulin requirements may vary and generally range from 0.5-1 units/kg.
When used in a meal-related subcutaneous injection regimen, 50-70% of the total daily insulin requirement may be provided by insulin aspart and the remainder by an intermediate-acting or long-acting insulin. Because of the comparatively rapid onset and short duration of activity of insulin aspart, some patients may require more basal insulin and more total daily insulin to prevent pre-meal hyperglycemia than when using insulin human (regular).
When insulin aspart is used in external infusion pumps, the initial dosage is based on the total daily insulin dosage of the previous regimen. Approximately 50% of the total dosage is given as meal-related injections and the remainder as a basal infusion. Adjustments in basal insulin injections or higher basal infusion rates may be necessary.
When insulin aspart in fixed combination with insulin aspart protamine is used as monotherapy in patients with type 1 or 2 diabetes mellitus, an initial total daily dosage of 0.4-0.6 units/kg given in 2 doses (before the morning and evening meal) has been recommended, with subsequent dosage titrated in increments of 2-4 units every 3-4 days to achieve the target fasting plasma glucose.
When the fixed combination of insulin aspart and insulin aspart protamine is given in combination with oral antidiabetic agents, an initial total daily dosage of 0.2-0.3 units/kg has been recommended, with subsequent dosage titration to target glycemic goals.
(See Treatment Goals under Uses: Diabetes Mellitus, in the Insulins General Statement 68:20.08.) Because of diurnal variation in insulin resistance and endogenous insulin secretion, variability in the time and content of meals, and variability in the time and extent of exercise, fixed-ratio insulin mixtures may not provide optimal glycemic control for all patients. The dose of the insulin mixture required to provide adequate glycemic control for one of the meals may result in hypoglycemia or hyperglycemia for the other meal. The pharmacodynamic profile of insulin aspart in fixed combination with insulin aspart protamine also may be inadequate for patients who require more frequent meals (e.g., pregnant women).
When the fixed combination of insulin aspart and insulin aspart protamine is used to replace isophane insulin alone or a biphasic insulin product (e.g., premixed isophane and regular insulin) in patients with adequate glycemic control, the initial dosage of insulin aspart in fixed combination with insulin aspart protamine should be identical to the previous insulin dosage, with subsequent adjustment of dosage as required. Patients inadequately controlled on isophane insulin may require increases of 10-20% in the dosage of the fixed combination of insulin aspart and insulin aspart protamine during the first week. In patients transferring from a multiple-daily-dose regimen consisting of an intermediate-acting (e.g., isophane) insulin and a rapid- or short-acting insulin at mealtimes, the initial dosage of the insulin aspart protamine component of the fixed combination should be same as the dosage of the previously used intermediate-acting insulin. Adjustments in the dosage or type of insulin may be needed during illness, emotional or physiologic stress, or changes in meals and exercise.
When used in a meal-related subcutaneous injection regimen, 50-70% of the total daily insulin requirement may be provided by insulin aspart and the remainder by an intermediate-acting or long-acting insulin. Because of the comparatively rapid onset and short duration of activity of insulin aspart, some patients may require more basal insulin and more total daily insulin to prevent pre-meal hyperglycemia than when using insulin human (regular).
When insulin aspart is used in external infusion pumps, the initial dosage is based on the total daily insulin dosage of the previous regimen. Approximately 50% of the total dosage is given as meal-related injections and the remainder as a basal infusion. Adjustments in basal insulin injections or higher basal infusion rates may be necessary.
When insulin aspart in fixed combination with insulin aspart protamine is used as monotherapy in patients with type 1 or 2 diabetes mellitus, an initial total daily dosage of 0.4-0.6 units/kg given in 2 doses (before the morning and evening meal) has been recommended, with subsequent dosage titrated in increments of 2-4 units every 3-4 days to achieve the target fasting plasma glucose.
When the fixed combination of insulin aspart and insulin aspart protamine is given in combination with oral antidiabetic agents, an initial total daily dosage of 0.2-0.3 units/kg has been recommended, with subsequent dosage titration to target glycemic goals.
(See Treatment Goals under Uses: Diabetes Mellitus, in the Insulins General Statement 68:20.08.) Because of diurnal variation in insulin resistance and endogenous insulin secretion, variability in the time and content of meals, and variability in the time and extent of exercise, fixed-ratio insulin mixtures may not provide optimal glycemic control for all patients. The dose of the insulin mixture required to provide adequate glycemic control for one of the meals may result in hypoglycemia or hyperglycemia for the other meal. The pharmacodynamic profile of insulin aspart in fixed combination with insulin aspart protamine also may be inadequate for patients who require more frequent meals (e.g., pregnant women).
When the fixed combination of insulin aspart and insulin aspart protamine is used to replace isophane insulin alone or a biphasic insulin product (e.g., premixed isophane and regular insulin) in patients with adequate glycemic control, the initial dosage of insulin aspart in fixed combination with insulin aspart protamine should be identical to the previous insulin dosage, with subsequent adjustment of dosage as required. Patients inadequately controlled on isophane insulin may require increases of 10-20% in the dosage of the fixed combination of insulin aspart and insulin aspart protamine during the first week. In patients transferring from a multiple-daily-dose regimen consisting of an intermediate-acting (e.g., isophane) insulin and a rapid- or short-acting insulin at mealtimes, the initial dosage of the insulin aspart protamine component of the fixed combination should be same as the dosage of the previously used intermediate-acting insulin. Adjustments in the dosage or type of insulin may be needed during illness, emotional or physiologic stress, or changes in meals and exercise.
Insulin aspart alone or in fixed combination with insulin aspart protamine is administered by subcutaneous injection using a conventional insulin syringe, an insulin injection pen (e.g., NovoPen(R) 3 PenMate, Novolog(R) FlexPen(R)), or a compatible insulin delivery device (Innovo(R), InDuo(R)). The manufacturer states that NovoLog(R) or Novolog Mix 70/30 PenFill(R) cartridges are intended for use with NovoPen(R) 3 PenMate(R) or a compatible insulin delivery device (Innovo(R), InDuo(R)). Insulin aspart also is administered by continuous subcutaneous infusion using an external controlled-infusion device (e.g., Minimed(R) model 500 series, Disetronic H-TRON series or other equivalent pump).
Insulin aspart is recommended for use in any reservoir and infusion sets that are compatible with insulin and the specific pump. Insulin aspart in fixed combination with insulin aspart protamine should not be used in insulin infusion pumps. For information on the stability of insulin aspart in external infusion pumps, see Insulin Aspart and Insulin Lispro under Chemistry and Stability: Stability, in the Insulins General Statement 68:20.08.
Because of its short duration of action, insulin aspart is used concomitantly with a longer-acting insulin (e.g., isophane (NPH) insulin human, insulin aspart protamine) to meet basal insulin needs in patients with diabetes mellitus and to provide more optimal glycemic control. Insulin aspart may be mixed with isophane insulin human. Although some attenuation of peak serum insulin aspart concentrations was observed when administered concomitantly with isophane insulin human in the same syringe, the time to peak concentration and total bioavailability of insulin aspart were not substantially affected.
Whenever insulin aspart is mixed with isophane insulin human, insulin aspart should be drawn into the syringe first in order to avoid transfer of isophane insulin human into the insulin vial. The mixture should be administered immediately after mixing, and such mixtures should not be administered IV. The manufacturer states that the effect of mixing insulin aspart with insulins of animal origin, insulins produced by other manufacturers, or crystalline insulin zinc formulations has not been studied.
The manufacturer states that insulin aspart in fixed combination with insulin aspart protamine suspension (Novolog(R) Mix 70/30) is intended only for subcutaneous administration and should not be given IV. To resuspend the mixture in a vial immediately before use, the vial should be rolled gently between the hands 10 times until the suspension appears to be uniformly white and cloudy. Before inserting the Novolog(R) PenFill(R) cartridge into a compatible delivery device, the cartridge should be rolled between the palms 10 times.
The cartridge should then be turned upside down so that the glass ball inside the cartridge moves the length of the cartridge. This rolling and turning of the cartridge should be repeated at least 10 times or until the suspension appears to be uniformly white and cloudy. The dose should be injected immediately after resuspension, and the rolling and turning of the cartridge should be repeated before each subsequent injection.
Similarly, if using the Novolog(R) FlexPen(R), the pen should be rolled between the palms 10 times. The injection pen should then be turned upside down so that the glass ball inside the pen moves from one end of the reservoir to the other. This rolling and turning procedure should be repeated at least 10 times or until the suspension appears uniformly white and cloudy.
The dose should be injected immediately after resuspension, and the rolling and turning of the FlexPen(R) should be repeated before each subsequent injection. Insulin aspart is administered immediately (within 5-10 minutes) before a meal. Insulin aspart in fixed combination with insulin aspart protamine (Novolog(R) Mix 70/30) generally is administered twice daily, 15 minutes before the morning and evening meals, with each dose intended to optimize glycemic control during 2 meals or a meal and a snack.
Insulin aspart can be administered by subcutaneous injection into the abdominal wall, thigh, or upper arm. A planned rotation of injection sites within an area should be followed. Insulin aspart may be administered by IV infusion under proper medical supervision in a clinical setting.
For IV infusion in polypropylene infusion bags, insulin aspart is usually diluted to a concentration of 0.05-1 units/mL in 0.9% sodium chloride, 5% dextrose, or 10% dextrose injection with 40 mEq/L of potassium chloride.
Insulin aspart is recommended for use in any reservoir and infusion sets that are compatible with insulin and the specific pump. Insulin aspart in fixed combination with insulin aspart protamine should not be used in insulin infusion pumps. For information on the stability of insulin aspart in external infusion pumps, see Insulin Aspart and Insulin Lispro under Chemistry and Stability: Stability, in the Insulins General Statement 68:20.08.
Because of its short duration of action, insulin aspart is used concomitantly with a longer-acting insulin (e.g., isophane (NPH) insulin human, insulin aspart protamine) to meet basal insulin needs in patients with diabetes mellitus and to provide more optimal glycemic control. Insulin aspart may be mixed with isophane insulin human. Although some attenuation of peak serum insulin aspart concentrations was observed when administered concomitantly with isophane insulin human in the same syringe, the time to peak concentration and total bioavailability of insulin aspart were not substantially affected.
Whenever insulin aspart is mixed with isophane insulin human, insulin aspart should be drawn into the syringe first in order to avoid transfer of isophane insulin human into the insulin vial. The mixture should be administered immediately after mixing, and such mixtures should not be administered IV. The manufacturer states that the effect of mixing insulin aspart with insulins of animal origin, insulins produced by other manufacturers, or crystalline insulin zinc formulations has not been studied.
The manufacturer states that insulin aspart in fixed combination with insulin aspart protamine suspension (Novolog(R) Mix 70/30) is intended only for subcutaneous administration and should not be given IV. To resuspend the mixture in a vial immediately before use, the vial should be rolled gently between the hands 10 times until the suspension appears to be uniformly white and cloudy. Before inserting the Novolog(R) PenFill(R) cartridge into a compatible delivery device, the cartridge should be rolled between the palms 10 times.
The cartridge should then be turned upside down so that the glass ball inside the cartridge moves the length of the cartridge. This rolling and turning of the cartridge should be repeated at least 10 times or until the suspension appears to be uniformly white and cloudy. The dose should be injected immediately after resuspension, and the rolling and turning of the cartridge should be repeated before each subsequent injection.
Similarly, if using the Novolog(R) FlexPen(R), the pen should be rolled between the palms 10 times. The injection pen should then be turned upside down so that the glass ball inside the pen moves from one end of the reservoir to the other. This rolling and turning procedure should be repeated at least 10 times or until the suspension appears uniformly white and cloudy.
The dose should be injected immediately after resuspension, and the rolling and turning of the FlexPen(R) should be repeated before each subsequent injection. Insulin aspart is administered immediately (within 5-10 minutes) before a meal. Insulin aspart in fixed combination with insulin aspart protamine (Novolog(R) Mix 70/30) generally is administered twice daily, 15 minutes before the morning and evening meals, with each dose intended to optimize glycemic control during 2 meals or a meal and a snack.
Insulin aspart can be administered by subcutaneous injection into the abdominal wall, thigh, or upper arm. A planned rotation of injection sites within an area should be followed. Insulin aspart may be administered by IV infusion under proper medical supervision in a clinical setting.
For IV infusion in polypropylene infusion bags, insulin aspart is usually diluted to a concentration of 0.05-1 units/mL in 0.9% sodium chloride, 5% dextrose, or 10% dextrose injection with 40 mEq/L of potassium chloride.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for NOVOLOG MIX 70-30 FLEXPEN (insulin aspart protamine human/insulin aspart):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
Drug Interaction | Drug Names |
---|---|
Antidiabetic Agents/Gatifloxacin SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The exact mechanism is unknown. CLINICAL EFFECTS: Concurrent use of gatifloxacin may result in hypoglycemia and/or hyperglycemia.(1-4) Hypoglycemia is more common during the first three days of concurrent therapy. Hyperglycemia is more common after the first three days of concurrent therapy.(2) PREDISPOSING FACTORS: Elderly patients, especially those with decreased renal function may be predisposed to this interaction.(2) PATIENT MANAGEMENT: Patients receiving concurrent gatifloxacin should be closely monitored for hypoglycemia during the first three days of concurrent therapy and for hyperglycemia after the first three days of concurrent therapy. Patients should be instructed to discontinue gatifloxacin if hypoglycemia or hyperglycemia occur.(2) DISCUSSION: Hypoglycemia has been reported with gatifloxacin and glyburide(1,5,6) or glimepiride.(7) In a study in patients with type 2 diabetes mellitus, concurrent gatifloxacin (400 mg daily for 10 days) had no effect on the pharmacokinetics of glyburide (steady state daily regimen); however, pharmacodynamic interactions have been reported.(2) Health Canada has received 19 reports of hypoglycemia in patients taking gatifloxacin. Seventeen of these involved concurrent hypoglycemic agents. Health Canada has received 2 reports of hyperglycemia in patients taking gatifloxacin and hypoglycemic agents. Health Canada has received 2 reports of patients experiencing hypoglycemia and hyperglycemia during concurrent gatifloxacin and hypoglycemic agents.(3) In a study, 13 reports of dysglycemia were reported in patients taking gatifloxacin. Ten of these patients had diabetes mellitus and were on concurrent hypoglycemic agents. Of these ten patients, nine patients experienced hypoglycemia, while one patient experienced hyperglycemia.(8) |
GATIFLOXACIN SESQUIHYDRATE |
There are 12 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
Drug Interaction | Drug Names |
---|---|
Antidiabetics/Epinephrine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Gluconeogenesis, glycogenolysis, and lipolysis are increased by epinephrine. Also, insulin secretion and glucose uptake by peripheral tissues are decreased by epinephrine. CLINICAL EFFECTS: Increased blood glucose resulting in decreased effectiveness of the antidiabetic agent. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Caution when starting or stopping epinephrine in diabetic patients. Adjust the antidiabetic dose as needed based on blood glucose levels. DISCUSSION: This interaction is likely to occur based upon well documented properties of the interacting drugs. However, there is individual variability in its occurrence. |
ADRENALIN, ARTICADENT DENTAL, ARTICAINE-EPINEPHRINE, ARTICAINE-EPINEPHRINE BIT, BUFFERED LIDOCAINE-EPINEPHRINE, BUPIVACAINE HCL-EPINEPHRINE, BUPIVACAINE-DEXAMETH-EPINEPHRN, CITANEST FORTE DENTAL, EPINEPHRINE, EPINEPHRINE BITARTR-0.9% NACL, EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE-NACL, EPINEPHRINE CONVENIENCE KIT, EPINEPHRINE HCL-0.9% NACL, EPINEPHRINE HCL-D5W, EPINEPHRINE-0.9% NACL, EPINEPHRINE-D5W, EPINEPHRINE-NACL, LIDOCAINE HCL-EPINEPHRINE, LIDOCAINE HCL-EPINEPHRINE-NACL, LIDOCAINE-EPINEPHRINE, LIGNOSPAN STANDARD, MARCAINE-EPINEPHRINE, ORABLOC, R.E.C.K.(ROPIV-EPI-CLON-KETOR), RACEPINEPHRINE HCL, SENSORCAINE-EPINEPHRINE, SENSORCAINE-MPF EPINEPHRINE, SEPTOCAINE, VIVACAINE, XYLOCAINE DENTAL-EPINEPHRINE, XYLOCAINE WITH EPINEPHRINE, XYLOCAINE-MPF WITH EPINEPHRINE |
Selected Antidiabetics/MAOIs SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The exact mechanism by which MAO inhibitors affect carbohydrate metabolism and subsequent enhancement of the hypoglycemic action of insulin is not clear. The adrenergic response to hypoglycemia may be blocked by insulin release caused by MAOI's. In vitro studies have shown that MAO inhibitors are capable of both potentiating and inhibiting insulin release, depending on their concentrations. Stimulation of glucose-mediated insulin secretion is believed to be related to the MAO inhibitory effects of the drugs. CLINICAL EFFECTS: The hypoglycemic response to both insulin and glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylurea may be increased. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Concurrent MAO inhibitor therapy for depression in a diabetic patient will often require reduction in dosage of the hypoglycemic agent because of enhanced hypoglycemic effects. Since the extent of the reaction is highly unpredictable, any diabetic patients receiving MAO inhibitors should be monitored for possible excessive hypoglycemia. DISCUSSION: This interaction is likely to occur. The interaction between MAOIs and insulin is well documented. Additional documentation is necessary to confirm the potential interaction of MAOI's with other glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylureas but is expected to occur based on pharmacologic similarity. It may take several weeks for the full hypoglycemic effect of the MAOI to occur. Conversely, it may take several weeks for the effect to dissipate after stopping the MAOI. Furazolidone is known to be a monoamine oxidase inhibitor. Methylene blue, when administered intravenously, has been shown to reach sufficient concentrations to be a potent inhibitor of MAO-A. Metaxalone is a weak inhibitor of MAO. |
AZILECT, EMSAM, FURAZOLIDONE, LINEZOLID, LINEZOLID-0.9% NACL, LINEZOLID-D5W, MARPLAN, MATULANE, METAXALONE, METHYLENE BLUE, NARDIL, PARNATE, PHENELZINE SULFATE, PROCARBAZINE HCL, PROVAYBLUE, RASAGILINE MESYLATE, SELEGILINE HCL, TRANYLCYPROMINE SULFATE, ZELAPAR, ZYVOX |
Thiazides/Antidiabetics SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Thiazides antagonize hypoglycemic effects of antidiabetics due to intrinsic hyperglycemic activity. CLINICAL EFFECTS: Impaired glucose tolerance and diminished hypoglycemic effects of antidiabetics may occur. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Caution when starting or stopping thiazides in diabetic patients. Adjust the antidiabetic dose as needed based on blood glucose levels. DISCUSSION: This interaction is likely to occur based upon well documented properties of the interacting drugs. However, there is individual variability in its occurrence. A cross-sectional study of 425 outpatients found 46 patients with 86 suspected drug interactions resulting in uncontrolled glycemia. Recorded drug interactions included hydrochlorothiazide-gliclazide (22.1%), hydrochlorothiazide-insulins (2.3%), and chlorothiazide-gliclazide (1.2%). Using the drug interaction probability scale (DIPS), these drug interactions were categorized as possible.(2) |
ACCURETIC, AMILORIDE-HYDROCHLOROTHIAZIDE, AMLODIPINE-VALSARTAN-HCTZ, ATACAND HCT, ATENOLOL-CHLORTHALIDONE, AVALIDE, BENAZEPRIL-HYDROCHLOROTHIAZIDE, BENICAR HCT, BISOPROLOL-HYDROCHLOROTHIAZIDE, CANDESARTAN-HYDROCHLOROTHIAZID, CAPTOPRIL-HYDROCHLOROTHIAZIDE, CHLOROTHIAZIDE, CHLOROTHIAZIDE SODIUM, CHLORTHALIDONE, DIOVAN HCT, DIURIL, EDARBYCLOR, ENALAPRIL-HYDROCHLOROTHIAZIDE, EXFORGE HCT, FOSINOPRIL-HYDROCHLOROTHIAZIDE, HEMICLOR, HYDROCHLOROTHIAZIDE, HYZAAR, INDAPAMIDE, INZIRQO, IRBESARTAN-HYDROCHLOROTHIAZIDE, LISINOPRIL-HYDROCHLOROTHIAZIDE, LOSARTAN-HYDROCHLOROTHIAZIDE, LOTENSIN HCT, METHYLDOPA-HYDROCHLOROTHIAZIDE, METOLAZONE, METOPROLOL-HYDROCHLOROTHIAZIDE, MICARDIS HCT, OLMESARTAN-AMLODIPINE-HCTZ, OLMESARTAN-HYDROCHLOROTHIAZIDE, PROPRANOLOL-HYDROCHLOROTHIAZID, QUINAPRIL-HYDROCHLOROTHIAZIDE, SPIRONOLACTONE-HCTZ, TELMISARTAN-HYDROCHLOROTHIAZID, TENORETIC 100, TENORETIC 50, THALITONE, TRIAMTERENE-HYDROCHLOROTHIAZID, TRIBENZOR, TRICHLORMETHIAZIDE, VALSARTAN-HYDROCHLOROTHIAZIDE, VASERETIC, ZESTORETIC |
Insulin/Fenfluramine;Dexfenfluramine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Fenfluramine increases glucose uptake at the receptor site (ie, skeletal muscle). CLINICAL EFFECTS: The hypoglycemic effect of insulin is increased. PREDISPOSING FACTORS: Diabetes. PATIENT MANAGEMENT: In diabetic patients receiving insulin, monitor blood glucose levels and observe the patient for signs of hypoglycemia when initiating therapy with fenfluramine and for symptoms of hyperglycemia when fenfluramine is discontinued. DISCUSSION: When administered before meals or to fasting patients, fenfluramine has been found to have hypoglycemic action. Numerous reports have demonstrated fenfluramine to potentiate the hypoglycemic effect of insulin in diabetic patients. |
FINTEPLA |
Pioglitazone/Insulin SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The exact mechanism is unknown, but may be the result of additive fluid retention.(1,2) CLINICAL EFFECTS: The concurrent use of pioglitazone with insulin may increase the risk of edema and heart failure.(1,2) PREDISPOSING FACTORS: Specific risk factors for heart failure could not be determined. Patients with ongoing edema are more likely to have edema-associated adverse effects with combination therapy.(1) PATIENT MANAGEMENT: Patients receiving concurrent therapy should be monitored for cardiovascular adverse events. If signs and symptoms of congestive heart failure develop, patients should be treated according to current standards of care. Consideration should be given to lowering the dosage of or discontinuing pioglitazone.(1,2) DISCUSSION: In a clinical trial, two of 191 (1.1%) of patients receiving pioglitazone (15 mg) and insulin and two of 188 (1.1%) of patients receiving pioglitazone (30 mg) and insulin developed congestive heart failure. None of the patients receiving insulin alone developed congestive heart failure.(1) |
ACTOPLUS MET, ACTOS, ALOGLIPTIN-PIOGLITAZONE, DUETACT, OSENI, PIOGLITAZONE HCL, PIOGLITAZONE-GLIMEPIRIDE, PIOGLITAZONE-METFORMIN |
Bupropion/Hypoglycemics; Insulin SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Bupropion can lower the seizure threshold and when given concurrently with other medications that also lower the threshold there is an increased risk of seizure.(1,2) CLINICAL EFFECTS: Concurrent use of bupropion and hypoglycemics or insulin may increase the risk of seizure.(1,2) PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants an anorectics; a total daily dose of bupropion greater than 450 mg or single doses greater than 150 mg; rapid escalation of bupropion dosage; or with concomitant medications known to lower seizure threshold (antidepressants, antipsychotics, systemic steroids, theophylline).(1,2) PATIENT MANAGEMENT: The use of bupropion in patients treated with oral hypoglycemic agents or insulin should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2) Single doses should not exceed 150 mg.(1,2) The maximum daily dose of bupropion should not exceed 300 mg for smoking cessation(2) or 450 mg for depression.(1) DISCUSSION: Because of the risk of seizure from concurrent bupropion and other agents that lower seizure threshold, the manufacturer of bupropion states that the concurrent use of bupropion and oral hypoglycemic agents or insulin should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2) |
APLENZIN, AUVELITY, BUPROPION HCL, BUPROPION HCL SR, BUPROPION XL, CONTRAVE, FORFIVO XL, WELLBUTRIN SR, WELLBUTRIN XL |
Selected Antidiabetic Agents/Selected Quinolones SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The exact mechanism is unknown. CLINICAL EFFECTS: Concurrent use of quinolones and antidiabetic agents may result in severe hypoglycemia.(1-7) Hypoglycemia can lead to coma. PREDISPOSING FACTORS: Elderly patients, especially those with decreased renal function may be predisposed to this interaction.(5) PATIENT MANAGEMENT: Patients maintained on antidiabetic agents who require concurrent therapy with a quinolone should be closely monitored for hypoglycemia.(1-4) Patients should be instructed to discontinue quinolone use and contact their doctor if hypoglycemia occurs.(2,4) Signs of hypoglycemia may include confusion, dizziness, feeling shaky, unusual hunger, headaches, irritability, pounding heart or very fast pulse, pale skin, sweating, trembling, weakness, or unusual anxiety. DISCUSSION: Hypoglycemia has been reported with concurrent ciprofloxacin and glyburide,(1,8,9) levofloxacin and glyburide,(2,10,11) norfloxacin and glyburide,(3) levofloxacin and glipizide (12) as well as levofloxacin and metformin-glibenclamide.(14) There has been one report of fatal hypoglycemia with concurrent levofloxacin and glyburide(9) and one of the above reports of hypoglycemia with concurrent levofloxacin and glyburide resulted in hypoxic brain injury.(11) A review of postmarketing adverse event data for the fluoroquinolones and hypoglycemic coma identified 56 reports in FAERS search from October 1987- April 2017 and 11 additional cases in the medical literature. Most patients had risk factors for hypoglycemia. 41 patients were taking one or more hypoglycemic drugs. 13 deaths occurred (some of these patients had renal insufficiency). 9 patients did not fully recover and had resultant disability.(13) |
AVELOX IV, BAXDELA, CIPRO, CIPROFLOXACIN, CIPROFLOXACIN HCL, CIPROFLOXACIN-D5W, LEVOFLOXACIN, LEVOFLOXACIN HEMIHYDRATE, LEVOFLOXACIN-D5W, MOXIFLOXACIN, MOXIFLOXACIN HCL, OFLOXACIN |
Antidiabetics/Selected Ophthalmic Non-Cardioselective Beta-Blockers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia.(1,2) CLINICAL EFFECTS: Diminished response to sulfonylureas and insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked.(1,2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia. DISCUSSION: A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo.(3) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(4) There have been case reports of hypoglycemia following the addition of ophthalmic timolol to a diabetic regimen.(5-7) Studies have shown that ophthalmic beta-blockers, especially the aqueous solution, have significant systemic absorption and do not undergo first-pass metabolism.(8,9) |
BETIMOL, BRIMONIDINE TARTRATE-TIMOLOL, CARTEOLOL HCL, COMBIGAN, COSOPT, COSOPT PF, DORZOLAMIDE-TIMOLOL, ISTALOL, LEVOBUNOLOL HCL, TIMOLOL, TIMOLOL MALEATE, TIMOLOL-BIMATOPROST, TIMOLOL-BRIMONI-DORZOL-BIMATOP, TIMOLOL-BRIMONIDIN-DORZOLAMIDE, TIMOLOL-DORZOLAMIDE-BIMATOPRST, TIMOPTIC OCUDOSE |
Insulin/Selected Systemic Non-Cardioselective Beta-Blockers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia. CLINICAL EFFECTS: Diminished response to insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia. DISCUSSION: A class effect of diminished glucose-lowering effects is expected with concurrent use of beta-blockers and insulin. It is prudent to monitor serum glucose closely in patients receiving beta-blocker therapy because symptoms of hypoglycemia may be masked. A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5 mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo. (1) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5 mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(2) |
BETAPACE, BETAPACE AF, CORGARD, HEMANGEOL, INDERAL LA, INDERAL XL, INNOPRAN XL, NADOLOL, PINDOLOL, PROPRANOLOL HCL, PROPRANOLOL HCL ER, PROPRANOLOL-HYDROCHLOROTHIAZID, SOTALOL, SOTALOL AF, SOTALOL HCL, SOTYLIZE, TIMOLOL MALEATE |
Insulin/Carvedilol; Labetalol SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia. CLINICAL EFFECTS: Diminished response to insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia. DISCUSSION: A class effect of diminished glucose-lowering effects is expected with concurrent use of beta-blockers and insulin. It is prudent to monitor serum glucose closely in patients receiving beta-blocker therapy because symptoms of hypoglycemia may be masked. A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5 mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo. (1) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5 mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(2) |
CARVEDILOL, CARVEDILOL ER, COREG, COREG CR, LABETALOL HCL, LABETALOL HCL-WATER |
Selected Antidiabetic Agents/Chloroquine; Hydroxychloroquine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The exact mechanism is unknown. Chloroquine and hydroxychloroquine may increase insulin sensitivity by inhibiting insulin metabolism and inflammation and increasing cellular uptake of glucose and glycogen synthesis.(1,2) These effects may result in additive hypoglycemia with anti-diabetic agents. CLINICAL EFFECTS: Concurrent use of chloroquine or hydroxychloroquine and antidiabetic agents may result in severe hypoglycemia.(3) Hypoglycemia can lead to coma. PREDISPOSING FACTORS: Elderly patients, especially those with decreased renal function may be predisposed to this interaction. PATIENT MANAGEMENT: Patients maintained on antidiabetic agents who require concurrent therapy with chloroquine or hydroxychloroquine should be closely monitored for hypoglycemia. A decrease in the dose of insulin or other anti-diabetic medications may be required. Patients should be advised of the risk and symptoms of hypoglycemia and to contact their doctor if hypoglycemia occurs.(3) Signs of hypoglycemia may include confusion, dizziness, feeling shaky, unusual hunger, headaches, irritability, pounding heart or very fast pulse, pale skin, sweating, trembling, weakness, or unusual anxiety. DISCUSSION: Hydroxychloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening.(3) Concomitant hypoglycemic agents may increase the risk and/or severity of this effect. A 77 year old man who was stable on twice daily insulin suffered two episodes of hypoglycemic coma 2 weeks after starting prednisone 5 mg daily and hydroxychloroquine 400 mg daily for rheumatoid arthritis. His insulin dosage required a decrease of 37%.(4) Many studies have investigated the glucose-lowering effect of hydroxychloroquine. In a clinical trial of type II diabetics on maximal doses of sulfonylureas, addition of hydroxychloroquine lowered hemoglobin A1C (HbA1C) up to 1% more than placebo.(5) Another clinical trial of type II diabetics on metformin and glimepiride or gliclazide found that hydroxychloroquine 400 mg daily reduced fasting blood glucose (FBG), post-prandial glucose (PPG), and HbA1C to a similar degree as pioglitazone 15 mg daily at 24 weeks.(6) In a prospective observational study, 250 uncontrolled type II diabetics on metformin, glimepiride, pioglitazone, sitagliptin, and a SGLT-2 inhibitor received hydroxychloroquine 400 mg daily for 48 weeks. HbA1C decreased from 8.83% to 6.44%, FBG decreased by 40.78%, and PPG decreased by 58.95%. The doses of metformin were reduced by 50%, glimepiride and sitagliptin by 75%, and SGLT-2 inhibitors were discontinued in most patients.(7) |
CHLOROQUINE PHOSPHATE, HYDROXYCHLOROQUINE SULFATE, PLAQUENIL, SOVUNA |
Selected Antidiabetics/Safinamide SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The exact mechanism by which MAO inhibitors such as safinamide affect carbohydrate metabolism and subsequent enhancement of the hypoglycemic action of insulin is not clear. The adrenergic response to hypoglycemia may be blocked by insulin release caused by MAOI's. In vitro studies have shown that MAO inhibitors are capable of both potentiating and inhibiting insulin release, depending on their concentrations. Stimulation of glucose-mediated insulin secretion is believed to be related to the MAO inhibitory effects of the drugs. CLINICAL EFFECTS: The hypoglycemic response to both insulin and glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylurea may be increased. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Concurrent MAO inhibitor therapy for depression in a diabetic patient will often require reduction in dosage of the hypoglycemic agent because of enhanced hypoglycemic effects. Since the extent of the reaction is highly unpredictable, any diabetic patients receiving MAO inhibitors should be monitored for possible excessive hypoglycemia. DISCUSSION: This interaction is likely to occur. The interaction between MAOIs and insulin is well documented. Additional documentation is necessary to confirm the potential interaction of MAOI's with other glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylureas but is expected to occur based on pharmacologic similarity. It may take several weeks for the full hypoglycemic effect of the MAOI to occur. Conversely, it may take several weeks for the effect to dissipate after stopping the MAOI. |
XADAGO |
The following contraindication information is available for NOVOLOG MIX 70-30 FLEXPEN (insulin aspart protamine human/insulin aspart):
Drug contraindication overview.
Known hypersensitivity to insulin aspart or any ingredient in the formulation. Contraindicated during episodes of hypoglycemia.
Known hypersensitivity to insulin aspart or any ingredient in the formulation. Contraindicated during episodes of hypoglycemia.
There are 0 contraindications.
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
Severe List |
---|
Hypoglycemic disorder |
There are 3 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
Moderate List |
---|
Disease of liver |
Hypokalemia |
Kidney disease with reduction in glomerular filtration rate (GFr) |
The following adverse reaction information is available for NOVOLOG MIX 70-30 FLEXPEN (insulin aspart protamine human/insulin aspart):
Adverse reaction overview.
Hypoglycemia, hypersensitivity reactions, lipodystrophy, pruritus, rash, and injection site reactions have been reported with insulin aspart monotherapy. In clinical studies, small but persistent elevations in alkaline phosphatase were observed in some patients with type 1 diabetes mellitus who received insulin aspart. However, the clinical importance, if any, of these findings has not been established.
Injection site reactions have been reported in 7% of patients receiving insulin aspart in fixed combination with insulin aspart protamine. Data from comparative clinical trials evaluating insulin aspart in fixed combination with insulin aspart protamine (Novolog(R) Mix 70/30) and insulin human (regular) injection in fixed combination with isophane insulin human (Novolin(R) 70/30) did not reveal differences in the frequency of adverse effects between the 2 preparations.
Hypoglycemia, hypersensitivity reactions, lipodystrophy, pruritus, rash, and injection site reactions have been reported with insulin aspart monotherapy. In clinical studies, small but persistent elevations in alkaline phosphatase were observed in some patients with type 1 diabetes mellitus who received insulin aspart. However, the clinical importance, if any, of these findings has not been established.
Injection site reactions have been reported in 7% of patients receiving insulin aspart in fixed combination with insulin aspart protamine. Data from comparative clinical trials evaluating insulin aspart in fixed combination with insulin aspart protamine (Novolog(R) Mix 70/30) and insulin human (regular) injection in fixed combination with isophane insulin human (Novolin(R) 70/30) did not reveal differences in the frequency of adverse effects between the 2 preparations.
There are 6 severe adverse reactions.
More Frequent | Less Frequent |
---|---|
Hypersensitivity drug reaction Hypoglycemic disorder |
None. |
Rare/Very Rare |
---|
Anaphylaxis Angioedema Hypokalemia Localized cutaneous amyloidosis |
There are 16 less severe adverse reactions.
More Frequent | Less Frequent |
---|---|
Headache disorder Hyporeflexia Lipodystrophy Pruritus of skin |
Acute abdominal pain Agnosia Chest pain Localized edema Peripheral edema Sinusitis Upper respiratory infection Urinary tract infection Weight gain |
Rare/Very Rare |
---|
Edema Injection site sequelae Skin rash |
The following precautions are available for NOVOLOG MIX 70-30 FLEXPEN (insulin aspart protamine human/insulin aspart):
Safety and efficacy of insulin aspart in fixed combination with insulin aspart protamine not established in children. The comparative safety and efficacy of insulin aspart and insulin human (regular) have been demonstrated in a 24-week clinical study in children and adolescents 6-18 years of age with type 1 diabetes mellitus; children also received isophane insulin as the basal insulin supplement. Glycemic control (as determined by glycosylated hemoglobin (hemoglobin A1c, HbA1c)) was comparable in patients receiving insulin aspart or insulin human.
In addition, safety and efficacy of insulin aspart were comparable with insulin human in another clinical study in adolescents 12-17 years of age with type 1 diabetes mellitus. In comparative study in a limited number of children 2-6 years of age, glycemic control (as measured by HbA1c, fructosamine) was comparable in children receiving insulin aspart or insulin human. As observed in the 6- to 18-year age group, the rates of hypoglycemia in children 2-6 years of age were similar with insulin aspart or insulin human. In one pharmacokinetic study, insulin aspart had a more rapid onset and a shorter duration of action when compared with insulin human in a limited number of children and adolescents 6-17 years of age; such effects are similar to those observed in adults.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
In addition, safety and efficacy of insulin aspart were comparable with insulin human in another clinical study in adolescents 12-17 years of age with type 1 diabetes mellitus. In comparative study in a limited number of children 2-6 years of age, glycemic control (as measured by HbA1c, fructosamine) was comparable in children receiving insulin aspart or insulin human. As observed in the 6- to 18-year age group, the rates of hypoglycemia in children 2-6 years of age were similar with insulin aspart or insulin human. In one pharmacokinetic study, insulin aspart had a more rapid onset and a shorter duration of action when compared with insulin human in a limited number of children and adolescents 6-17 years of age; such effects are similar to those observed in adults.
Contraindicated
None |
Severe Precaution
None |
Management or Monitoring Precaution
None |
Category C. (See Users' Guide.)
It is unknown whether insulin aspart is distributed into milk; caution is advised if used in nursing women.
Experience in those 65 years of age and older insufficient to determine whether safety differs from younger adults. Efficacy of insulin aspart (as measured by HbA1c) as compared to insulin human appears to be similar in geriatric and younger patients, particularly in patients with type 2 diabetes mellitus.
The following prioritized warning is available for NOVOLOG MIX 70-30 FLEXPEN (insulin aspart protamine human/insulin aspart):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for NOVOLOG MIX 70-30 FLEXPEN (insulin aspart protamine human/insulin aspart)'s list of indications:
Diabetes mellitus | |
E08 | Diabetes mellitus due to underlying condition |
E08.0 | Diabetes mellitus due to underlying condition with hyperosmolarity |
E08.00 | Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
E08.01 | Diabetes mellitus due to underlying condition with hyperosmolarity with coma |
E08.1 | Diabetes mellitus due to underlying condition with ketoacidosis |
E08.10 | Diabetes mellitus due to underlying condition with ketoacidosis without coma |
E08.11 | Diabetes mellitus due to underlying condition with ketoacidosis with coma |
E08.2 | Diabetes mellitus due to underlying condition with kidney complications |
E08.21 | Diabetes mellitus due to underlying condition with diabetic nephropathy |
E08.22 | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease |
E08.29 | Diabetes mellitus due to underlying condition with other diabetic kidney complication |
E08.3 | Diabetes mellitus due to underlying condition with ophthalmic complications |
E08.31 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy |
E08.311 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema |
E08.319 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema |
E08.32 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy |
E08.321 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema |
E08.3211 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E08.3212 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E08.3213 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E08.3219 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E08.329 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema |
E08.3291 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E08.3292 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E08.3293 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E08.3299 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E08.33 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy |
E08.331 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema |
E08.3311 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E08.3312 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E08.3313 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E08.3319 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E08.339 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema |
E08.3391 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E08.3392 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E08.3393 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E08.3399 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E08.34 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy |
E08.341 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema |
E08.3411 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E08.3412 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E08.3413 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E08.3419 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E08.349 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema |
E08.3491 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E08.3492 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E08.3493 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E08.3499 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E08.35 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy |
E08.351 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema |
E08.3511 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye |
E08.3512 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye |
E08.3513 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral |
E08.3519 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye |
E08.352 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E08.3521 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E08.3522 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E08.3523 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E08.3529 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E08.353 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E08.3531 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E08.3532 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E08.3533 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E08.3539 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E08.354 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E08.3541 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E08.3542 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E08.3543 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E08.3549 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E08.355 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy |
E08.3551 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye |
E08.3552 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye |
E08.3553 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral |
E08.3559 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye |
E08.359 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema |
E08.3591 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye |
E08.3592 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye |
E08.3593 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral |
E08.3599 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye |
E08.36 | Diabetes mellitus due to underlying condition with diabetic cataract |
E08.37 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment |
E08.37x1 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye |
E08.37x2 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye |
E08.37x3 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral |
E08.37x9 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye |
E08.39 | Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication |
E08.4 | Diabetes mellitus due to underlying condition with neurological complications |
E08.40 | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified |
E08.41 | Diabetes mellitus due to underlying condition with diabetic mononeuropathy |
E08.42 | Diabetes mellitus due to underlying condition with diabetic polyneuropathy |
E08.43 | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy |
E08.44 | Diabetes mellitus due to underlying condition with diabetic amyotrophy |
E08.49 | Diabetes mellitus due to underlying condition with other diabetic neurological complication |
E08.5 | Diabetes mellitus due to underlying condition with circulatory complications |
E08.51 | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene |
E08.52 | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene |
E08.59 | Diabetes mellitus due to underlying condition with other circulatory complications |
E08.6 | Diabetes mellitus due to underlying condition with other specified complications |
E08.61 | Diabetes mellitus due to underlying condition with diabetic arthropathy |
E08.610 | Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy |
E08.618 | Diabetes mellitus due to underlying condition with other diabetic arthropathy |
E08.62 | Diabetes mellitus due to underlying condition with skin complications |
E08.620 | Diabetes mellitus due to underlying condition with diabetic dermatitis |
E08.621 | Diabetes mellitus due to underlying condition with foot ulcer |
E08.622 | Diabetes mellitus due to underlying condition with other skin ulcer |
E08.628 | Diabetes mellitus due to underlying condition with other skin complications |
E08.63 | Diabetes mellitus due to underlying condition with oral complications |
E08.630 | Diabetes mellitus due to underlying condition with periodontal disease |
E08.638 | Diabetes mellitus due to underlying condition with other oral complications |
E08.64 | Diabetes mellitus due to underlying condition with hypoglycemia |
E08.641 | Diabetes mellitus due to underlying condition with hypoglycemia with coma |
E08.649 | Diabetes mellitus due to underlying condition with hypoglycemia without coma |
E08.65 | Diabetes mellitus due to underlying condition with hyperglycemia |
E08.69 | Diabetes mellitus due to underlying condition with other specified complication |
E08.8 | Diabetes mellitus due to underlying condition with unspecified complications |
E08.9 | Diabetes mellitus due to underlying condition without complications |
E09 | Drug or chemical induced diabetes mellitus |
E09.0 | Drug or chemical induced diabetes mellitus with hyperosmolarity |
E09.00 | Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
E09.01 | Drug or chemical induced diabetes mellitus with hyperosmolarity with coma |
E09.1 | Drug or chemical induced diabetes mellitus with ketoacidosis |
E09.10 | Drug or chemical induced diabetes mellitus with ketoacidosis without coma |
E09.11 | Drug or chemical induced diabetes mellitus with ketoacidosis with coma |
E09.2 | Drug or chemical induced diabetes mellitus with kidney complications |
E09.21 | Drug or chemical induced diabetes mellitus with diabetic nephropathy |
E09.22 | Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease |
E09.29 | Drug or chemical induced diabetes mellitus with other diabetic kidney complication |
E09.3 | Drug or chemical induced diabetes mellitus with ophthalmic complications |
E09.31 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy |
E09.311 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema |
E09.319 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema |
E09.32 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy |
E09.321 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
E09.3211 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E09.3212 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E09.3213 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E09.3219 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E09.329 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
E09.3291 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E09.3292 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E09.3293 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E09.3299 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E09.33 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy |
E09.331 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
E09.3311 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E09.3312 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E09.3313 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E09.3319 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E09.339 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
E09.3391 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E09.3392 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E09.3393 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E09.3399 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E09.34 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy |
E09.341 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
E09.3411 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E09.3412 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E09.3413 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E09.3419 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E09.349 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
E09.3491 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E09.3492 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E09.3493 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E09.3499 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E09.35 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy |
E09.351 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema |
E09.3511 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
E09.3512 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
E09.3513 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
E09.3519 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
E09.352 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E09.3521 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E09.3522 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E09.3523 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E09.3529 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E09.353 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E09.3531 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E09.3532 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E09.3533 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E09.3539 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E09.354 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E09.3541 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E09.3542 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E09.3543 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E09.3549 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E09.355 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy |
E09.3551 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
E09.3552 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
E09.3553 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
E09.3559 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
E09.359 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema |
E09.3591 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
E09.3592 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
E09.3593 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
E09.3599 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
E09.36 | Drug or chemical induced diabetes mellitus with diabetic cataract |
E09.37 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment |
E09.37x1 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
E09.37x2 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
E09.37x3 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
E09.37x9 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
E09.39 | Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication |
E09.4 | Drug or chemical induced diabetes mellitus with neurological complications |
E09.40 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified |
E09.41 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy |
E09.42 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy |
E09.43 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy |
E09.44 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy |
E09.49 | Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication |
E09.5 | Drug or chemical induced diabetes mellitus with circulatory complications |
E09.51 | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene |
E09.52 | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene |
E09.59 | Drug or chemical induced diabetes mellitus with other circulatory complications |
E09.6 | Drug or chemical induced diabetes mellitus with other specified complications |
E09.61 | Drug or chemical induced diabetes mellitus with diabetic arthropathy |
E09.610 | Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy |
E09.618 | Drug or chemical induced diabetes mellitus with other diabetic arthropathy |
E09.62 | Drug or chemical induced diabetes mellitus with skin complications |
E09.620 | Drug or chemical induced diabetes mellitus with diabetic dermatitis |
E09.621 | Drug or chemical induced diabetes mellitus with foot ulcer |
E09.622 | Drug or chemical induced diabetes mellitus with other skin ulcer |
E09.628 | Drug or chemical induced diabetes mellitus with other skin complications |
E09.63 | Drug or chemical induced diabetes mellitus with oral complications |
E09.630 | Drug or chemical induced diabetes mellitus with periodontal disease |
E09.638 | Drug or chemical induced diabetes mellitus with other oral complications |
E09.64 | Drug or chemical induced diabetes mellitus with hypoglycemia |
E09.641 | Drug or chemical induced diabetes mellitus with hypoglycemia with coma |
E09.649 | Drug or chemical induced diabetes mellitus with hypoglycemia without coma |
E09.65 | Drug or chemical induced diabetes mellitus with hyperglycemia |
E09.69 | Drug or chemical induced diabetes mellitus with other specified complication |
E09.8 | Drug or chemical induced diabetes mellitus with unspecified complications |
E09.9 | Drug or chemical induced diabetes mellitus without complications |
E10 | Type 1 diabetes mellitus |
E10.1 | Type 1 diabetes mellitus with ketoacidosis |
E10.10 | Type 1 diabetes mellitus with ketoacidosis without coma |
E10.11 | Type 1 diabetes mellitus with ketoacidosis with coma |
E10.2 | Type 1 diabetes mellitus with kidney complications |
E10.21 | Type 1 diabetes mellitus with diabetic nephropathy |
E10.22 | Type 1 diabetes mellitus with diabetic chronic kidney disease |
E10.29 | Type 1 diabetes mellitus with other diabetic kidney complication |
E10.3 | Type 1 diabetes mellitus with ophthalmic complications |
E10.31 | Type 1 diabetes mellitus with unspecified diabetic retinopathy |
E10.311 | Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
E10.319 | Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema |
E10.32 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy |
E10.321 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
E10.3211 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E10.3212 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E10.3213 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E10.3219 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E10.329 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
E10.3291 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E10.3292 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E10.3293 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E10.3299 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E10.33 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy |
E10.331 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
E10.3311 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E10.3312 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E10.3313 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E10.3319 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E10.339 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
E10.3391 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E10.3392 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E10.3393 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E10.3399 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E10.34 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy |
E10.341 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
E10.3411 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E10.3412 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E10.3413 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E10.3419 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E10.349 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
E10.3491 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E10.3492 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E10.3493 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E10.3499 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E10.35 | Type 1 diabetes mellitus with proliferative diabetic retinopathy |
E10.351 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
E10.3511 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
E10.3512 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
E10.3513 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
E10.3519 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
E10.352 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E10.3521 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E10.3522 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E10.3523 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E10.3529 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E10.353 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E10.3531 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E10.3532 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E10.3533 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E10.3539 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E10.354 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E10.3541 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E10.3542 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E10.3543 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E10.3549 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E10.355 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy |
E10.3551 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
E10.3552 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
E10.3553 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
E10.3559 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
E10.359 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema |
E10.3591 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
E10.3592 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
E10.3593 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
E10.3599 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
E10.36 | Type 1 diabetes mellitus with diabetic cataract |
E10.37 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment |
E10.37x1 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
E10.37x2 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
E10.37x3 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
E10.37x9 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
E10.39 | Type 1 diabetes mellitus with other diabetic ophthalmic complication |
E10.4 | Type 1 diabetes mellitus with neurological complications |
E10.40 | Type 1 diabetes mellitus with diabetic neuropathy, unspecified |
E10.41 | Type 1 diabetes mellitus with diabetic mononeuropathy |
E10.42 | Type 1 diabetes mellitus with diabetic polyneuropathy |
E10.43 | Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy |
E10.44 | Type 1 diabetes mellitus with diabetic amyotrophy |
E10.49 | Type 1 diabetes mellitus with other diabetic neurological complication |
E10.5 | Type 1 diabetes mellitus with circulatory complications |
E10.51 | Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene |
E10.52 | Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene |
E10.59 | Type 1 diabetes mellitus with other circulatory complications |
E10.6 | Type 1 diabetes mellitus with other specified complications |
E10.61 | Type 1 diabetes mellitus with diabetic arthropathy |
E10.610 | Type 1 diabetes mellitus with diabetic neuropathic arthropathy |
E10.618 | Type 1 diabetes mellitus with other diabetic arthropathy |
E10.62 | Type 1 diabetes mellitus with skin complications |
E10.620 | Type 1 diabetes mellitus with diabetic dermatitis |
E10.621 | Type 1 diabetes mellitus with foot ulcer |
E10.622 | Type 1 diabetes mellitus with other skin ulcer |
E10.628 | Type 1 diabetes mellitus with other skin complications |
E10.63 | Type 1 diabetes mellitus with oral complications |
E10.630 | Type 1 diabetes mellitus with periodontal disease |
E10.638 | Type 1 diabetes mellitus with other oral complications |
E10.64 | Type 1 diabetes mellitus with hypoglycemia |
E10.641 | Type 1 diabetes mellitus with hypoglycemia with coma |
E10.649 | Type 1 diabetes mellitus with hypoglycemia without coma |
E10.65 | Type 1 diabetes mellitus with hyperglycemia |
E10.69 | Type 1 diabetes mellitus with other specified complication |
E10.8 | Type 1 diabetes mellitus with unspecified complications |
E10.9 | Type 1 diabetes mellitus without complications |
E10.A | Type 1 diabetes mellitus, presymptomatic |
E10.A0 | Type 1 diabetes mellitus, presymptomatic, unspecified |
E10.A1 | Type 1 diabetes mellitus, presymptomatic, stage 1 |
E10.A2 | Type 1 diabetes mellitus, presymptomatic, stage 2 |
E11 | Type 2 diabetes mellitus |
E11.0 | Type 2 diabetes mellitus with hyperosmolarity |
E11.00 | Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
E11.01 | Type 2 diabetes mellitus with hyperosmolarity with coma |
E11.1 | Type 2 diabetes mellitus with ketoacidosis |
E11.10 | Type 2 diabetes mellitus with ketoacidosis without coma |
E11.11 | Type 2 diabetes mellitus with ketoacidosis with coma |
E11.2 | Type 2 diabetes mellitus with kidney complications |
E11.21 | Type 2 diabetes mellitus with diabetic nephropathy |
E11.22 | Type 2 diabetes mellitus with diabetic chronic kidney disease |
E11.29 | Type 2 diabetes mellitus with other diabetic kidney complication |
E11.3 | Type 2 diabetes mellitus with ophthalmic complications |
E11.31 | Type 2 diabetes mellitus with unspecified diabetic retinopathy |
E11.311 | Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
E11.319 | Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema |
E11.32 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy |
E11.321 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
E11.3211 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E11.3212 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E11.3213 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E11.3219 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E11.329 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
E11.3291 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E11.3292 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E11.3293 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E11.3299 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E11.33 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy |
E11.331 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
E11.3311 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E11.3312 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E11.3313 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E11.3319 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E11.339 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
E11.3391 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E11.3392 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E11.3393 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E11.3399 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E11.34 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy |
E11.341 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
E11.3411 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E11.3412 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E11.3413 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E11.3419 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E11.349 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
E11.3491 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E11.3492 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E11.3493 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E11.3499 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E11.35 | Type 2 diabetes mellitus with proliferative diabetic retinopathy |
E11.351 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
E11.3511 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
E11.3512 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
E11.3513 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
E11.3519 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
E11.352 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E11.3521 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E11.3522 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E11.3523 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E11.3529 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E11.353 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E11.3531 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E11.3532 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E11.3533 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E11.3539 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E11.354 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E11.3541 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E11.3542 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E11.3543 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E11.3549 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E11.355 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy |
E11.3551 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
E11.3552 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
E11.3553 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
E11.3559 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
E11.359 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema |
E11.3591 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
E11.3592 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
E11.3593 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
E11.3599 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
E11.36 | Type 2 diabetes mellitus with diabetic cataract |
E11.37 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment |
E11.37x1 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
E11.37x2 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
E11.37x3 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
E11.37x9 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
E11.39 | Type 2 diabetes mellitus with other diabetic ophthalmic complication |
E11.4 | Type 2 diabetes mellitus with neurological complications |
E11.40 | Type 2 diabetes mellitus with diabetic neuropathy, unspecified |
E11.41 | Type 2 diabetes mellitus with diabetic mononeuropathy |
E11.42 | Type 2 diabetes mellitus with diabetic polyneuropathy |
E11.43 | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy |
E11.44 | Type 2 diabetes mellitus with diabetic amyotrophy |
E11.49 | Type 2 diabetes mellitus with other diabetic neurological complication |
E11.5 | Type 2 diabetes mellitus with circulatory complications |
E11.51 | Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene |
E11.52 | Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene |
E11.59 | Type 2 diabetes mellitus with other circulatory complications |
E11.6 | Type 2 diabetes mellitus with other specified complications |
E11.61 | Type 2 diabetes mellitus with diabetic arthropathy |
E11.610 | Type 2 diabetes mellitus with diabetic neuropathic arthropathy |
E11.618 | Type 2 diabetes mellitus with other diabetic arthropathy |
E11.62 | Type 2 diabetes mellitus with skin complications |
E11.620 | Type 2 diabetes mellitus with diabetic dermatitis |
E11.621 | Type 2 diabetes mellitus with foot ulcer |
E11.622 | Type 2 diabetes mellitus with other skin ulcer |
E11.628 | Type 2 diabetes mellitus with other skin complications |
E11.63 | Type 2 diabetes mellitus with oral complications |
E11.630 | Type 2 diabetes mellitus with periodontal disease |
E11.638 | Type 2 diabetes mellitus with other oral complications |
E11.64 | Type 2 diabetes mellitus with hypoglycemia |
E11.641 | Type 2 diabetes mellitus with hypoglycemia with coma |
E11.649 | Type 2 diabetes mellitus with hypoglycemia without coma |
E11.65 | Type 2 diabetes mellitus with hyperglycemia |
E11.69 | Type 2 diabetes mellitus with other specified complication |
E11.8 | Type 2 diabetes mellitus with unspecified complications |
E11.9 | Type 2 diabetes mellitus without complications |
E13 | Other specified diabetes mellitus |
E13.0 | Other specified diabetes mellitus with hyperosmolarity |
E13.00 | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
E13.01 | Other specified diabetes mellitus with hyperosmolarity with coma |
E13.1 | Other specified diabetes mellitus with ketoacidosis |
E13.10 | Other specified diabetes mellitus with ketoacidosis without coma |
E13.11 | Other specified diabetes mellitus with ketoacidosis with coma |
E13.2 | Other specified diabetes mellitus with kidney complications |
E13.21 | Other specified diabetes mellitus with diabetic nephropathy |
E13.22 | Other specified diabetes mellitus with diabetic chronic kidney disease |
E13.29 | Other specified diabetes mellitus with other diabetic kidney complication |
E13.3 | Other specified diabetes mellitus with ophthalmic complications |
E13.31 | Other specified diabetes mellitus with unspecified diabetic retinopathy |
E13.311 | Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema |
E13.319 | Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema |
E13.32 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy |
E13.321 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
E13.3211 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E13.3212 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E13.3213 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E13.3219 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E13.329 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
E13.3291 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E13.3292 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E13.3293 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E13.3299 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E13.33 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy |
E13.331 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
E13.3311 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E13.3312 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E13.3313 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E13.3319 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E13.339 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
E13.3391 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E13.3392 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E13.3393 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E13.3399 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E13.34 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy |
E13.341 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
E13.3411 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E13.3412 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E13.3413 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E13.3419 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E13.349 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
E13.3491 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E13.3492 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E13.3493 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E13.3499 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E13.35 | Other specified diabetes mellitus with proliferative diabetic retinopathy |
E13.351 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema |
E13.3511 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
E13.3512 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
E13.3513 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
E13.3519 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
E13.352 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E13.3521 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E13.3522 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E13.3523 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E13.3529 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E13.353 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E13.3531 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E13.3532 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E13.3533 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E13.3539 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E13.354 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E13.3541 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E13.3542 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E13.3543 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E13.3549 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E13.355 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy |
E13.3551 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
E13.3552 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
E13.3553 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
E13.3559 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
E13.359 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema |
E13.3591 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
E13.3592 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
E13.3593 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
E13.3599 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
E13.36 | Other specified diabetes mellitus with diabetic cataract |
E13.37 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment |
E13.37x1 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
E13.37x2 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
E13.37x3 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
E13.37x9 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
E13.39 | Other specified diabetes mellitus with other diabetic ophthalmic complication |
E13.4 | Other specified diabetes mellitus with neurological complications |
E13.40 | Other specified diabetes mellitus with diabetic neuropathy, unspecified |
E13.41 | Other specified diabetes mellitus with diabetic mononeuropathy |
E13.42 | Other specified diabetes mellitus with diabetic polyneuropathy |
E13.43 | Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy |
E13.44 | Other specified diabetes mellitus with diabetic amyotrophy |
E13.49 | Other specified diabetes mellitus with other diabetic neurological complication |
E13.5 | Other specified diabetes mellitus with circulatory complications |
E13.51 | Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene |
E13.52 | Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene |
E13.59 | Other specified diabetes mellitus with other circulatory complications |
E13.6 | Other specified diabetes mellitus with other specified complications |
E13.61 | Other specified diabetes mellitus with diabetic arthropathy |
E13.610 | Other specified diabetes mellitus with diabetic neuropathic arthropathy |
E13.618 | Other specified diabetes mellitus with other diabetic arthropathy |
E13.62 | Other specified diabetes mellitus with skin complications |
E13.620 | Other specified diabetes mellitus with diabetic dermatitis |
E13.621 | Other specified diabetes mellitus with foot ulcer |
E13.622 | Other specified diabetes mellitus with other skin ulcer |
E13.628 | Other specified diabetes mellitus with other skin complications |
E13.63 | Other specified diabetes mellitus with oral complications |
E13.630 | Other specified diabetes mellitus with periodontal disease |
E13.638 | Other specified diabetes mellitus with other oral complications |
E13.64 | Other specified diabetes mellitus with hypoglycemia |
E13.641 | Other specified diabetes mellitus with hypoglycemia with coma |
E13.649 | Other specified diabetes mellitus with hypoglycemia without coma |
E13.65 | Other specified diabetes mellitus with hyperglycemia |
E13.69 | Other specified diabetes mellitus with other specified complication |
E13.8 | Other specified diabetes mellitus with unspecified complications |
E13.9 | Other specified diabetes mellitus without complications |
O24 | Diabetes mellitus in pregnancy, childbirth, and the puerperium |
O24.0 | Pre-existing type 1 diabetes mellitus, in pregnancy, childbirth and the puerperium |
O24.01 | Pre-existing type 1 diabetes mellitus, in pregnancy |
O24.011 | Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester |
O24.012 | Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester |
O24.013 | Pre-existing type 1 diabetes mellitus, in pregnancy, third trimester |
O24.019 | Pre-existing type 1 diabetes mellitus, in pregnancy, unspecified trimester |
O24.02 | Pre-existing type 1 diabetes mellitus, in childbirth |
O24.03 | Pre-existing type 1 diabetes mellitus, in the puerperium |
O24.1 | Pre-existing type 2 diabetes mellitus, in pregnancy, childbirth and the puerperium |
O24.11 | Pre-existing type 2 diabetes mellitus, in pregnancy |
O24.111 | Pre-existing type 2 diabetes mellitus, in pregnancy, first trimester |
O24.112 | Pre-existing type 2 diabetes mellitus, in pregnancy, second trimester |
O24.113 | Pre-existing type 2 diabetes mellitus, in pregnancy, third trimester |
O24.119 | Pre-existing type 2 diabetes mellitus, in pregnancy, unspecified trimester |
O24.12 | Pre-existing type 2 diabetes mellitus, in childbirth |
O24.13 | Pre-existing type 2 diabetes mellitus, in the puerperium |
O24.3 | Unspecified pre-existing diabetes mellitus in pregnancy, childbirth and the puerperium |
O24.31 | Unspecified pre-existing diabetes mellitus in pregnancy |
O24.311 | Unspecified pre-existing diabetes mellitus in pregnancy, first trimester |
O24.312 | Unspecified pre-existing diabetes mellitus in pregnancy, second trimester |
O24.313 | Unspecified pre-existing diabetes mellitus in pregnancy, third trimester |
O24.319 | Unspecified pre-existing diabetes mellitus in pregnancy, unspecified trimester |
O24.32 | Unspecified pre-existing diabetes mellitus in childbirth |
O24.33 | Unspecified pre-existing diabetes mellitus in the puerperium |
O24.4 | Gestational diabetes mellitus |
O24.41 | Gestational diabetes mellitus in pregnancy |
O24.414 | Gestational diabetes mellitus in pregnancy, insulin controlled |
O24.415 | Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs |
O24.419 | Gestational diabetes mellitus in pregnancy, unspecified control |
O24.42 | Gestational diabetes mellitus in childbirth |
O24.424 | Gestational diabetes mellitus in childbirth, insulin controlled |
O24.425 | Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs |
O24.429 | Gestational diabetes mellitus in childbirth, unspecified control |
O24.43 | Gestational diabetes mellitus in the puerperium |
O24.434 | Gestational diabetes mellitus in the puerperium, insulin controlled |
O24.435 | Gestational diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs |
O24.439 | Gestational diabetes mellitus in the puerperium, unspecified control |
O24.8 | Other pre-existing diabetes mellitus in pregnancy, childbirth, and the puerperium |
O24.81 | Other pre-existing diabetes mellitus in pregnancy |
O24.811 | Other pre-existing diabetes mellitus in pregnancy, first trimester |
O24.812 | Other pre-existing diabetes mellitus in pregnancy, second trimester |
O24.813 | Other pre-existing diabetes mellitus in pregnancy, third trimester |
O24.819 | Other pre-existing diabetes mellitus in pregnancy, unspecified trimester |
O24.82 | Other pre-existing diabetes mellitus in childbirth |
O24.83 | Other pre-existing diabetes mellitus in the puerperium |
O24.9 | Unspecified diabetes mellitus in pregnancy, childbirth and the puerperium |
O24.91 | Unspecified diabetes mellitus in pregnancy |
O24.911 | Unspecified diabetes mellitus in pregnancy, first trimester |
O24.912 | Unspecified diabetes mellitus in pregnancy, second trimester |
O24.913 | Unspecified diabetes mellitus in pregnancy, third trimester |
O24.919 | Unspecified diabetes mellitus in pregnancy, unspecified trimester |
O24.92 | Unspecified diabetes mellitus in childbirth |
O24.93 | Unspecified diabetes mellitus in the puerperium |
P70.2 | Neonatal diabetes mellitus |
Type 1 diabetes mellitus | |
E10 | Type 1 diabetes mellitus |
E10.1 | Type 1 diabetes mellitus with ketoacidosis |
E10.10 | Type 1 diabetes mellitus with ketoacidosis without coma |
E10.11 | Type 1 diabetes mellitus with ketoacidosis with coma |
E10.2 | Type 1 diabetes mellitus with kidney complications |
E10.21 | Type 1 diabetes mellitus with diabetic nephropathy |
E10.22 | Type 1 diabetes mellitus with diabetic chronic kidney disease |
E10.29 | Type 1 diabetes mellitus with other diabetic kidney complication |
E10.3 | Type 1 diabetes mellitus with ophthalmic complications |
E10.31 | Type 1 diabetes mellitus with unspecified diabetic retinopathy |
E10.311 | Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
E10.319 | Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema |
E10.32 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy |
E10.321 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
E10.3211 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E10.3212 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E10.3213 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E10.3219 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E10.329 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
E10.3291 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E10.3292 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E10.3293 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E10.3299 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E10.33 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy |
E10.331 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
E10.3311 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E10.3312 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E10.3313 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E10.3319 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E10.339 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
E10.3391 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E10.3392 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E10.3393 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E10.3399 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E10.34 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy |
E10.341 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
E10.3411 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E10.3412 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E10.3413 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E10.3419 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E10.349 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
E10.3491 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E10.3492 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E10.3493 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E10.3499 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E10.35 | Type 1 diabetes mellitus with proliferative diabetic retinopathy |
E10.351 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
E10.3511 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
E10.3512 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
E10.3513 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
E10.3519 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
E10.352 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E10.3521 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E10.3522 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E10.3523 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E10.3529 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E10.353 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E10.3531 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E10.3532 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E10.3533 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E10.3539 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E10.354 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E10.3541 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E10.3542 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E10.3543 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E10.3549 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E10.355 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy |
E10.3551 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
E10.3552 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
E10.3553 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
E10.3559 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
E10.359 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema |
E10.3591 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
E10.3592 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
E10.3593 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
E10.3599 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
E10.36 | Type 1 diabetes mellitus with diabetic cataract |
E10.37 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment |
E10.37x1 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
E10.37x2 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
E10.37x3 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
E10.37x9 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
E10.39 | Type 1 diabetes mellitus with other diabetic ophthalmic complication |
E10.4 | Type 1 diabetes mellitus with neurological complications |
E10.40 | Type 1 diabetes mellitus with diabetic neuropathy, unspecified |
E10.41 | Type 1 diabetes mellitus with diabetic mononeuropathy |
E10.42 | Type 1 diabetes mellitus with diabetic polyneuropathy |
E10.43 | Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy |
E10.44 | Type 1 diabetes mellitus with diabetic amyotrophy |
E10.49 | Type 1 diabetes mellitus with other diabetic neurological complication |
E10.5 | Type 1 diabetes mellitus with circulatory complications |
E10.51 | Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene |
E10.52 | Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene |
E10.59 | Type 1 diabetes mellitus with other circulatory complications |
E10.6 | Type 1 diabetes mellitus with other specified complications |
E10.61 | Type 1 diabetes mellitus with diabetic arthropathy |
E10.610 | Type 1 diabetes mellitus with diabetic neuropathic arthropathy |
E10.618 | Type 1 diabetes mellitus with other diabetic arthropathy |
E10.62 | Type 1 diabetes mellitus with skin complications |
E10.620 | Type 1 diabetes mellitus with diabetic dermatitis |
E10.621 | Type 1 diabetes mellitus with foot ulcer |
E10.622 | Type 1 diabetes mellitus with other skin ulcer |
E10.628 | Type 1 diabetes mellitus with other skin complications |
E10.63 | Type 1 diabetes mellitus with oral complications |
E10.630 | Type 1 diabetes mellitus with periodontal disease |
E10.638 | Type 1 diabetes mellitus with other oral complications |
E10.64 | Type 1 diabetes mellitus with hypoglycemia |
E10.641 | Type 1 diabetes mellitus with hypoglycemia with coma |
E10.649 | Type 1 diabetes mellitus with hypoglycemia without coma |
E10.65 | Type 1 diabetes mellitus with hyperglycemia |
E10.69 | Type 1 diabetes mellitus with other specified complication |
E10.8 | Type 1 diabetes mellitus with unspecified complications |
E10.9 | Type 1 diabetes mellitus without complications |
E10.A | Type 1 diabetes mellitus, presymptomatic |
E10.A0 | Type 1 diabetes mellitus, presymptomatic, unspecified |
E10.A1 | Type 1 diabetes mellitus, presymptomatic, stage 1 |
E10.A2 | Type 1 diabetes mellitus, presymptomatic, stage 2 |
Type 2 diabetes mellitus | |
E08 | Diabetes mellitus due to underlying condition |
E08.0 | Diabetes mellitus due to underlying condition with hyperosmolarity |
E08.00 | Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
E08.01 | Diabetes mellitus due to underlying condition with hyperosmolarity with coma |
E08.1 | Diabetes mellitus due to underlying condition with ketoacidosis |
E08.10 | Diabetes mellitus due to underlying condition with ketoacidosis without coma |
E08.11 | Diabetes mellitus due to underlying condition with ketoacidosis with coma |
E08.2 | Diabetes mellitus due to underlying condition with kidney complications |
E08.21 | Diabetes mellitus due to underlying condition with diabetic nephropathy |
E08.22 | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease |
E08.29 | Diabetes mellitus due to underlying condition with other diabetic kidney complication |
E08.3 | Diabetes mellitus due to underlying condition with ophthalmic complications |
E08.31 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy |
E08.311 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema |
E08.319 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema |
E08.32 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy |
E08.321 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema |
E08.3211 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E08.3212 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E08.3213 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E08.3219 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E08.329 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema |
E08.3291 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E08.3292 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E08.3293 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E08.3299 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E08.33 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy |
E08.331 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema |
E08.3311 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E08.3312 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E08.3313 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E08.3319 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E08.339 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema |
E08.3391 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E08.3392 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E08.3393 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E08.3399 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E08.34 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy |
E08.341 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema |
E08.3411 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E08.3412 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E08.3413 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E08.3419 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E08.349 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema |
E08.3491 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E08.3492 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E08.3493 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E08.3499 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E08.35 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy |
E08.351 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema |
E08.3511 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye |
E08.3512 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye |
E08.3513 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral |
E08.3519 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye |
E08.352 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E08.3521 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E08.3522 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E08.3523 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E08.3529 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E08.353 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E08.3531 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E08.3532 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E08.3533 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E08.3539 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E08.354 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E08.3541 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E08.3542 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E08.3543 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E08.3549 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E08.355 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy |
E08.3551 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye |
E08.3552 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye |
E08.3553 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral |
E08.3559 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye |
E08.359 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema |
E08.3591 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye |
E08.3592 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye |
E08.3593 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral |
E08.3599 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye |
E08.36 | Diabetes mellitus due to underlying condition with diabetic cataract |
E08.37 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment |
E08.37x1 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye |
E08.37x2 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye |
E08.37x3 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral |
E08.37x9 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye |
E08.39 | Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication |
E08.4 | Diabetes mellitus due to underlying condition with neurological complications |
E08.40 | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified |
E08.41 | Diabetes mellitus due to underlying condition with diabetic mononeuropathy |
E08.42 | Diabetes mellitus due to underlying condition with diabetic polyneuropathy |
E08.43 | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy |
E08.44 | Diabetes mellitus due to underlying condition with diabetic amyotrophy |
E08.49 | Diabetes mellitus due to underlying condition with other diabetic neurological complication |
E08.5 | Diabetes mellitus due to underlying condition with circulatory complications |
E08.51 | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene |
E08.52 | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene |
E08.59 | Diabetes mellitus due to underlying condition with other circulatory complications |
E08.6 | Diabetes mellitus due to underlying condition with other specified complications |
E08.61 | Diabetes mellitus due to underlying condition with diabetic arthropathy |
E08.610 | Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy |
E08.618 | Diabetes mellitus due to underlying condition with other diabetic arthropathy |
E08.62 | Diabetes mellitus due to underlying condition with skin complications |
E08.620 | Diabetes mellitus due to underlying condition with diabetic dermatitis |
E08.621 | Diabetes mellitus due to underlying condition with foot ulcer |
E08.622 | Diabetes mellitus due to underlying condition with other skin ulcer |
E08.628 | Diabetes mellitus due to underlying condition with other skin complications |
E08.63 | Diabetes mellitus due to underlying condition with oral complications |
E08.630 | Diabetes mellitus due to underlying condition with periodontal disease |
E08.638 | Diabetes mellitus due to underlying condition with other oral complications |
E08.64 | Diabetes mellitus due to underlying condition with hypoglycemia |
E08.641 | Diabetes mellitus due to underlying condition with hypoglycemia with coma |
E08.649 | Diabetes mellitus due to underlying condition with hypoglycemia without coma |
E08.65 | Diabetes mellitus due to underlying condition with hyperglycemia |
E08.69 | Diabetes mellitus due to underlying condition with other specified complication |
E08.8 | Diabetes mellitus due to underlying condition with unspecified complications |
E08.9 | Diabetes mellitus due to underlying condition without complications |
E09 | Drug or chemical induced diabetes mellitus |
E09.0 | Drug or chemical induced diabetes mellitus with hyperosmolarity |
E09.00 | Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
E09.01 | Drug or chemical induced diabetes mellitus with hyperosmolarity with coma |
E09.1 | Drug or chemical induced diabetes mellitus with ketoacidosis |
E09.10 | Drug or chemical induced diabetes mellitus with ketoacidosis without coma |
E09.11 | Drug or chemical induced diabetes mellitus with ketoacidosis with coma |
E09.2 | Drug or chemical induced diabetes mellitus with kidney complications |
E09.21 | Drug or chemical induced diabetes mellitus with diabetic nephropathy |
E09.22 | Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease |
E09.29 | Drug or chemical induced diabetes mellitus with other diabetic kidney complication |
E09.3 | Drug or chemical induced diabetes mellitus with ophthalmic complications |
E09.31 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy |
E09.311 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema |
E09.319 | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema |
E09.32 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy |
E09.321 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
E09.3211 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E09.3212 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E09.3213 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E09.3219 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E09.329 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
E09.3291 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E09.3292 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E09.3293 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E09.3299 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E09.33 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy |
E09.331 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
E09.3311 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E09.3312 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E09.3313 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E09.3319 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E09.339 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
E09.3391 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E09.3392 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E09.3393 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E09.3399 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E09.34 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy |
E09.341 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
E09.3411 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E09.3412 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E09.3413 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E09.3419 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E09.349 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
E09.3491 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E09.3492 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E09.3493 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E09.3499 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E09.35 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy |
E09.351 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema |
E09.3511 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
E09.3512 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
E09.3513 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
E09.3519 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
E09.352 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E09.3521 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E09.3522 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E09.3523 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E09.3529 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E09.353 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E09.3531 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E09.3532 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E09.3533 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E09.3539 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E09.354 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E09.3541 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E09.3542 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E09.3543 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E09.3549 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E09.355 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy |
E09.3551 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
E09.3552 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
E09.3553 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
E09.3559 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
E09.359 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema |
E09.3591 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
E09.3592 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
E09.3593 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
E09.3599 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
E09.36 | Drug or chemical induced diabetes mellitus with diabetic cataract |
E09.37 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment |
E09.37x1 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
E09.37x2 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
E09.37x3 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
E09.37x9 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
E09.39 | Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication |
E09.4 | Drug or chemical induced diabetes mellitus with neurological complications |
E09.40 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified |
E09.41 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy |
E09.42 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy |
E09.43 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy |
E09.44 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy |
E09.49 | Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication |
E09.5 | Drug or chemical induced diabetes mellitus with circulatory complications |
E09.51 | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene |
E09.52 | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene |
E09.59 | Drug or chemical induced diabetes mellitus with other circulatory complications |
E09.6 | Drug or chemical induced diabetes mellitus with other specified complications |
E09.61 | Drug or chemical induced diabetes mellitus with diabetic arthropathy |
E09.610 | Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy |
E09.618 | Drug or chemical induced diabetes mellitus with other diabetic arthropathy |
E09.62 | Drug or chemical induced diabetes mellitus with skin complications |
E09.620 | Drug or chemical induced diabetes mellitus with diabetic dermatitis |
E09.621 | Drug or chemical induced diabetes mellitus with foot ulcer |
E09.622 | Drug or chemical induced diabetes mellitus with other skin ulcer |
E09.628 | Drug or chemical induced diabetes mellitus with other skin complications |
E09.63 | Drug or chemical induced diabetes mellitus with oral complications |
E09.630 | Drug or chemical induced diabetes mellitus with periodontal disease |
E09.638 | Drug or chemical induced diabetes mellitus with other oral complications |
E09.64 | Drug or chemical induced diabetes mellitus with hypoglycemia |
E09.641 | Drug or chemical induced diabetes mellitus with hypoglycemia with coma |
E09.649 | Drug or chemical induced diabetes mellitus with hypoglycemia without coma |
E09.65 | Drug or chemical induced diabetes mellitus with hyperglycemia |
E09.69 | Drug or chemical induced diabetes mellitus with other specified complication |
E09.8 | Drug or chemical induced diabetes mellitus with unspecified complications |
E09.9 | Drug or chemical induced diabetes mellitus without complications |
E11 | Type 2 diabetes mellitus |
E11.0 | Type 2 diabetes mellitus with hyperosmolarity |
E11.00 | Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
E11.01 | Type 2 diabetes mellitus with hyperosmolarity with coma |
E11.1 | Type 2 diabetes mellitus with ketoacidosis |
E11.10 | Type 2 diabetes mellitus with ketoacidosis without coma |
E11.11 | Type 2 diabetes mellitus with ketoacidosis with coma |
E11.2 | Type 2 diabetes mellitus with kidney complications |
E11.21 | Type 2 diabetes mellitus with diabetic nephropathy |
E11.22 | Type 2 diabetes mellitus with diabetic chronic kidney disease |
E11.29 | Type 2 diabetes mellitus with other diabetic kidney complication |
E11.3 | Type 2 diabetes mellitus with ophthalmic complications |
E11.31 | Type 2 diabetes mellitus with unspecified diabetic retinopathy |
E11.311 | Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
E11.319 | Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema |
E11.32 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy |
E11.321 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
E11.3211 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E11.3212 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E11.3213 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E11.3219 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E11.329 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
E11.3291 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E11.3292 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E11.3293 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E11.3299 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E11.33 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy |
E11.331 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
E11.3311 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E11.3312 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E11.3313 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E11.3319 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E11.339 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
E11.3391 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E11.3392 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E11.3393 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E11.3399 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E11.34 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy |
E11.341 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
E11.3411 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E11.3412 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E11.3413 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E11.3419 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E11.349 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
E11.3491 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E11.3492 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E11.3493 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E11.3499 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E11.35 | Type 2 diabetes mellitus with proliferative diabetic retinopathy |
E11.351 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
E11.3511 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
E11.3512 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
E11.3513 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
E11.3519 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
E11.352 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E11.3521 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E11.3522 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E11.3523 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E11.3529 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E11.353 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E11.3531 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E11.3532 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E11.3533 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E11.3539 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E11.354 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E11.3541 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E11.3542 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E11.3543 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E11.3549 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E11.355 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy |
E11.3551 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
E11.3552 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
E11.3553 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
E11.3559 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
E11.359 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema |
E11.3591 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
E11.3592 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
E11.3593 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
E11.3599 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
E11.36 | Type 2 diabetes mellitus with diabetic cataract |
E11.37 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment |
E11.37x1 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
E11.37x2 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
E11.37x3 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
E11.37x9 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
E11.39 | Type 2 diabetes mellitus with other diabetic ophthalmic complication |
E11.4 | Type 2 diabetes mellitus with neurological complications |
E11.40 | Type 2 diabetes mellitus with diabetic neuropathy, unspecified |
E11.41 | Type 2 diabetes mellitus with diabetic mononeuropathy |
E11.42 | Type 2 diabetes mellitus with diabetic polyneuropathy |
E11.43 | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy |
E11.44 | Type 2 diabetes mellitus with diabetic amyotrophy |
E11.49 | Type 2 diabetes mellitus with other diabetic neurological complication |
E11.5 | Type 2 diabetes mellitus with circulatory complications |
E11.51 | Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene |
E11.52 | Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene |
E11.59 | Type 2 diabetes mellitus with other circulatory complications |
E11.6 | Type 2 diabetes mellitus with other specified complications |
E11.61 | Type 2 diabetes mellitus with diabetic arthropathy |
E11.610 | Type 2 diabetes mellitus with diabetic neuropathic arthropathy |
E11.618 | Type 2 diabetes mellitus with other diabetic arthropathy |
E11.62 | Type 2 diabetes mellitus with skin complications |
E11.620 | Type 2 diabetes mellitus with diabetic dermatitis |
E11.621 | Type 2 diabetes mellitus with foot ulcer |
E11.622 | Type 2 diabetes mellitus with other skin ulcer |
E11.628 | Type 2 diabetes mellitus with other skin complications |
E11.63 | Type 2 diabetes mellitus with oral complications |
E11.630 | Type 2 diabetes mellitus with periodontal disease |
E11.638 | Type 2 diabetes mellitus with other oral complications |
E11.64 | Type 2 diabetes mellitus with hypoglycemia |
E11.641 | Type 2 diabetes mellitus with hypoglycemia with coma |
E11.649 | Type 2 diabetes mellitus with hypoglycemia without coma |
E11.65 | Type 2 diabetes mellitus with hyperglycemia |
E11.69 | Type 2 diabetes mellitus with other specified complication |
E11.8 | Type 2 diabetes mellitus with unspecified complications |
E11.9 | Type 2 diabetes mellitus without complications |
E13 | Other specified diabetes mellitus |
E13.0 | Other specified diabetes mellitus with hyperosmolarity |
E13.00 | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
E13.01 | Other specified diabetes mellitus with hyperosmolarity with coma |
E13.1 | Other specified diabetes mellitus with ketoacidosis |
E13.10 | Other specified diabetes mellitus with ketoacidosis without coma |
E13.11 | Other specified diabetes mellitus with ketoacidosis with coma |
E13.2 | Other specified diabetes mellitus with kidney complications |
E13.21 | Other specified diabetes mellitus with diabetic nephropathy |
E13.22 | Other specified diabetes mellitus with diabetic chronic kidney disease |
E13.29 | Other specified diabetes mellitus with other diabetic kidney complication |
E13.3 | Other specified diabetes mellitus with ophthalmic complications |
E13.31 | Other specified diabetes mellitus with unspecified diabetic retinopathy |
E13.311 | Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema |
E13.319 | Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema |
E13.32 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy |
E13.321 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
E13.3211 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
E13.3212 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
E13.3213 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
E13.3219 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E13.329 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
E13.3291 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
E13.3292 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
E13.3293 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
E13.3299 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E13.33 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy |
E13.331 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
E13.3311 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
E13.3312 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
E13.3313 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
E13.3319 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E13.339 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
E13.3391 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
E13.3392 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
E13.3393 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
E13.3399 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E13.34 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy |
E13.341 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
E13.3411 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
E13.3412 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
E13.3413 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
E13.3419 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
E13.349 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
E13.3491 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
E13.3492 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
E13.3493 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
E13.3499 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
E13.35 | Other specified diabetes mellitus with proliferative diabetic retinopathy |
E13.351 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema |
E13.3511 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
E13.3512 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
E13.3513 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
E13.3519 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
E13.352 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
E13.3521 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
E13.3522 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
E13.3523 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
E13.3529 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
E13.353 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
E13.3531 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
E13.3532 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
E13.3533 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
E13.3539 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
E13.354 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
E13.3541 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
E13.3542 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
E13.3543 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
E13.3549 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
E13.355 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy |
E13.3551 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
E13.3552 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
E13.3553 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
E13.3559 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
E13.359 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema |
E13.3591 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
E13.3592 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
E13.3593 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
E13.3599 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
E13.36 | Other specified diabetes mellitus with diabetic cataract |
E13.37 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment |
E13.37x1 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
E13.37x2 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
E13.37x3 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
E13.37x9 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
E13.39 | Other specified diabetes mellitus with other diabetic ophthalmic complication |
E13.4 | Other specified diabetes mellitus with neurological complications |
E13.40 | Other specified diabetes mellitus with diabetic neuropathy, unspecified |
E13.41 | Other specified diabetes mellitus with diabetic mononeuropathy |
E13.42 | Other specified diabetes mellitus with diabetic polyneuropathy |
E13.43 | Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy |
E13.44 | Other specified diabetes mellitus with diabetic amyotrophy |
E13.49 | Other specified diabetes mellitus with other diabetic neurological complication |
E13.5 | Other specified diabetes mellitus with circulatory complications |
E13.51 | Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene |
E13.52 | Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene |
E13.59 | Other specified diabetes mellitus with other circulatory complications |
E13.6 | Other specified diabetes mellitus with other specified complications |
E13.61 | Other specified diabetes mellitus with diabetic arthropathy |
E13.610 | Other specified diabetes mellitus with diabetic neuropathic arthropathy |
E13.618 | Other specified diabetes mellitus with other diabetic arthropathy |
E13.62 | Other specified diabetes mellitus with skin complications |
E13.620 | Other specified diabetes mellitus with diabetic dermatitis |
E13.621 | Other specified diabetes mellitus with foot ulcer |
E13.622 | Other specified diabetes mellitus with other skin ulcer |
E13.628 | Other specified diabetes mellitus with other skin complications |
E13.63 | Other specified diabetes mellitus with oral complications |
E13.630 | Other specified diabetes mellitus with periodontal disease |
E13.638 | Other specified diabetes mellitus with other oral complications |
E13.64 | Other specified diabetes mellitus with hypoglycemia |
E13.641 | Other specified diabetes mellitus with hypoglycemia with coma |
E13.649 | Other specified diabetes mellitus with hypoglycemia without coma |
E13.65 | Other specified diabetes mellitus with hyperglycemia |
E13.69 | Other specified diabetes mellitus with other specified complication |
E13.8 | Other specified diabetes mellitus with unspecified complications |
E13.9 | Other specified diabetes mellitus without complications |
Formulary Reference Tool